Publications by authors named "F Fougerousse"

Background: The effects of α and ß adrenergic receptor modulation on the risk of developing heart failure (HF) remains uncertain due to a lack of randomized controlled trials. This study aimed to estimate the effects of α and ß adrenergic receptors modulation on the risk of HF and to provide proof of principle for genetic target validation studies in HF.

Methods: Genetic variants within the cis regions encoding the adrenergic receptors α1A, α2B, ß1, and ß2 associated with blood pressure in a 757,601-participant genome-wide association study (GWAS) were selected as instruments to perform a drug target Mendelian randomization study.

View Article and Find Full Text PDF
Article Synopsis
  • The HERMES consortium is focused on understanding the genomic and molecular factors that contribute to heart failure by analyzing data from a large number of studies worldwide.
  • It includes 51 studies from 11 countries, gathering data from over 68,000 heart failure cases and nearly 950,000 controls, with broad demographic representation and long follow-up periods.
  • The main goals are to identify genetic risk factors for heart failure, explore causal pathways, and create tools to help stratify patients and predict risks based on their genetic information.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates whether reducing heart rate (HRR) can counteract cardiovascular dysfunction that occurs during acute decompensated heart failure (ADHF) in a rat model.
  • Researchers induced ADHF through salt-loading and evaluated cardiac output, myocardial perfusion, and coronary relaxation at multiple time points after treatment with an I current inhibitor (S38844).
  • Results showed that HRR significantly improved cardiac function metrics compared to untreated ADHF, suggesting that HRR may help mitigate the negative effects of ADHF.
View Article and Find Full Text PDF

MicroRNA (miRNA) inhibition is a promising therapeutic strategy in several disease indications. MRG-110 is a locked nucleic acid-based antisense oligonucleotide that targets miR-92a-3p and experimentally was shown to have documented therapeutic effects on cardiovascular disease and wound healing. To gain first insights into the activity of anti-miR-92a in humans, we investigated miR-92a-3p expression in several blood compartments and assessed the effect of MRG-110 on target derepression.

View Article and Find Full Text PDF

Background: Heart rate (HR) at admission in patients with acute heart failure (AHF) has been shown to be an important risk marker of in-hospital mortality. However, its relation with mid and long-term prognosis as well as the impact of Ejection Fraction (EF) is unknown. Our objective was to study the relationship between long-term survival and HR at admission depending on EF in a cohort of patients hospitalized for AHF.

View Article and Find Full Text PDF